A New Era of Guidance for One of the Most Challenging Patient Populations
Difficult-to-treat depression (DTD) represents one of the most complex and burdensome conditions in psychiatry. These are patients who continue to experience significant symptoms despite multiple evidence-based treatments, including medications, psychotherapy, and neuromodulation approaches such as transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT).
A recently published international expert consensus statement, co-authored by investigators from leading centers worldwide—including our team at UTHealth Houston—provides much-needed clinical guidance on the use of vagus nerve stimulation (VNS) in this population.
What Is Difficult-to-Treat Depression (DTD)?
DTD extends beyond traditional definitions of treatment-resistant depression (TRD). It includes patients who:
These patients face higher risks of hospitalization, suicidality, and mortality, as well as substantial functional impairment and healthcare costs.
Importantly, DTD reflects a clinical turning point—a moment when both clinician and patient recognize that new strategies are needed.
Where Does Vagus Nerve Stimulation Fit?
Vagus nerve stimulation is a neuromodulation treatment involving implantation of a device (similar to a pacemaker) that delivers electrical stimulation to the left vagus nerve in the neck.
Unlike treatments such as ECT or ketamine, VNS is not designed for rapid symptom relief. Instead, it is a long-term, disease-modifying strategy.
According to the expert panel, the primary goals of VNS are:
Notably, experts agreed that acute antidepressant effects should not be expected, as benefits may take months to emerge.
What Does the Evidence Show?
One of the most compelling aspects of VNS is its durability of effect.
A large 5-year registry study showed:
Additionally, improvements in quality of life were observed beyond symptom reduction.
More recently, the RECOVER trial, a randomized, sham-controlled study, further supported the role of VNS, particularly for long-term outcomes, even though early endpoints were less robust.
Which Patients Should Be Considered?
One of the most valuable contributions of this consensus statement is clarifying patient selection.
Strong candidates for VNS include:
Experts also highlighted that VNS may be particularly useful in patients:
Importantly, ECT non-response is not a contraindication.
What About Complex Clinical Scenarios?
The consensus provides nuanced guidance for real-world patients:
These insights are particularly valuable, as such patients are often excluded from clinical trials but commonly seen in practice.
How Should VNS Be Integrated into Treatment?
The panel emphasizes that VNS should be part of a comprehensive, longitudinal treatment plan, not a standalone intervention.
Key recommendations include:
Interestingly, the consensus strongly supports the idea that:
👉 VNS is a long-term stabilization strategy, while other treatments manage acute episodes
Rethinking the Treatment Timeline in Depression
This expert consensus challenges a common paradigm in psychiatry: the focus on short-term symptom relief.
Instead, it reframes VNS as:
This perspective is particularly aligned with the mission of the Center for Interventional Psychiatry at UTHealth Houston, where we aim to build comprehensive, stage-based care pathways for treatment-resistant depression.
Final Thoughts
Difficult-to-treat depression requires a shift in how we think about treatment—from sequential trials of acute therapies to integrated, long-term strategies.
Vagus nerve stimulation represents one of the most promising tools in this space, particularly for patients who have exhausted conventional options.
This global expert consensus provides practical, experience-based guidance that helps bridge the gap between clinical trials and real-world practice—bringing us one step closer to personalized, durable care for patients with severe depression.
Reference
McAllister-Williams RH, Alva G, Banov M, et al.
The Use of Vagus Nerve Stimulation (VNS) in the Management of Patients with Difficult-to-Treat Major Depressive Disorder (MDD): An Expert Consensus Statement.
Neuropsychiatric Disease and Treatment. 2026.
Contact
Request for Second Opinion Form – https://Go.uth.edu/CIPIntake
Phone – (713) 486-2621
Fax – (713) 500-2728
E-mail – [email protected]
Website: https://go.uth.edu/CIP
Disclaimer
This article was created with the assistance of artificial intelligence (AI) to help organize and refine the presentation of scientific information. All medical and scientific content has been reviewed and approved by Joao L. de Quevedo, MD, PhD, Director of the Center for Interventional Psychiatry at the John S. Dunn Behavioral Sciences Center at UTHealth Houston. The content is intended for educational and informational purposes only and does not substitute for professional medical advice.